OUTTHUNDER BETA

NAUT

buy Researched 2026-10-27 19:33 UTC

PriceDayYTD
Oct 26 close 2.44
Now 15:33 ET 2.99
+22.3%+53.1%

Trend

3.952.400.8518↑ 3.952.44≤ 2.10Volume29.6MClose21-day50-day200-dayBuy zoneApr 28Jul 29Oct 26

At $2.44, NAUT is 16.8% (0.77 ATR) above its rising 21-day average of $2.09 and 71.5% (2.22 ATR) above its rising 50-day average of $1.42.

Bull case
  • Q3 results beat estimates, and the company said 2026 revenue should exceed its prior roughly $500,000 outlook; $114.3 million in cash and investments is expected to fund operations into Q1 2028.
  • ARPA-H consortium participation could bring up to $6 million to support Voyager research in Alzheimer’s disease and cancer.
  • The planned Voyager beta unit by year-end and 2027 launch and shipment schedule offer concrete product milestones that could advance commercialization.
Bear case
  • The $125 million ATM creates a potential selling and dilution overhang: the filing’s $1.12 illustration implies 111.6 million new shares, about 88% more shares and roughly 47% dilution to existing holders’ proportional ownership. The results report no ATM sales through September 30, but do not settle how much or when Nautilus may sell; the capacity is not a completed sale.
  • Reported revenue of $234,000 remains small against a $15.636 million net loss, and commercialization depends on future execution. The fundamentals data endpoint is unavailable, limiting assessment of valuation and other financial measures.
  • The price is 71.5% (2.22 ATR) above its 50-day average, leaving room for a pullback; biotech risk appetite is weak, with XBI underperforming SPY by 2.16% over one month. NAUT’s low 0.18 correlation with XBI limits how much that driver explains its moves.
Reconciliation

The positive October 27 results and ARPA-H news contrast with the October 26 selloff, reported as 17.28%; I give more weight to the unresolved ATM overhang and closing-price setup, while today’s in-progress $2.96 is 21.3% (1.13 ATR) above $2.44—not a closing confirmation.

Decision

Asked: I don't own it. I'm considering buying it for the long term.

  • Action: buy
  • Condition: Buy on a daily close at or below $2.10.
  • Timing: Wait for a pullback rather than own it now, accepting that the order may never fill and further upside may be missed; buying now means holding through elevated volatility and unresolved potential share issuance.
  • Distance: $2.10 is 13.9% below $2.44, or 0.74 ATR; that move is routine for this instrument.
  • If-not-met: If the condition has not occurred by December 31, remain uninvested and reassess after the expected Voyager beta-unit milestone.
  • Invalidation: A company-reported delay of the Voyager beta unit beyond year-end would invalidate the product-timing leg of the thesis.
  • Forecast: 0.56 probability of beating SPY through the first post-earnings close; better-than-estimate Q3 results and ARPA-H support move it above 0.50, while dilution uncertainty and weak biotech risk appetite limit confidence.

Technical analysis: computed from daily prices as of 2026-10-26. Not an input to the decision above: each is scored against SPY on its own.

  • MACD (12, 26, 9): BULLISH, above its signal line, crossed 51 sessions ago (2026-08-13). Line 0.39, signal 0.34, histogram +0.05 and narrowing.
  • Awesome Oscillator (5, 34): BULLISH, above zero, crossed 31 sessions ago (2026-09-11). +1.05 and rising.
  • Chaikin Money Flow (20): BULLISH, buying pressure: volume is backing the up days, crossed 8 sessions ago (2026-10-14). +0.09 and falling.

Review triggers

  • Review-by: December 31, 2026 — estimated Voyager beta unit expected by year-end.
  • Price-below: $2.10 daily close.
  • Price-above: $3.95 daily close, the 52-week high.
  • Volume-above: 2,920K shares (95th-percentile threshold; already exceeded in the latest session).

Scaling in: consider building this entry in parts (dollar-cost averaging) rather than as a single order — for example, split the amount across several sessions or either side of the review date (December 31, 2026 — estimated Voyager beta unit expected by year-end.).

Dive deep

Market overview of 2026-10-27 18:16 UTC →